id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2008-P-0411-0021,FDA,FDA-2008-P-0411,"FDA Office of Policy to Novo Nordisk, Inc. - Petition Reconsideration & Petition for Stay of Action Denial",Other,PDN-Petition Denial,2009-06-18T04:00:00Z,2009,6,2009-06-18T04:00:00Z,,2013-07-27T22:47:20Z,,0,0,09000064809d2328
FDA-2008-P-0411-0018,FDA,FDA-2008-P-0411,"Exhibit 1 - ""Caraco Letter to FDA/CDER , re: ANDA 77-571/Repaglinide, May 29, 2009"" - [Caraco Pharmaceuticals Laboratories, LTD - (Winston & Strawn LLP) - Reply Comment] re FDA-2008-P-0411-0017",Supporting & Related Material,RC-Reply Comment (Supporting and Related Material),2009-06-17T04:00:00Z,2009,6,,,2009-06-18T00:15:06Z,,0,0,09000064809d05f7
FDA-2008-P-0411-0020,FDA,FDA-2008-P-0411,"Exhibit 3 - ""Caraco's Motion and Brief in Support of Motion Requesting Leave to Supplement Answer and CounterClaims, Civil Action No. 2:05 CV 40188"" - [Caraco Pharmaceuticals Laboratories, LTD - (Winston & Strawn LLP) - Reply Comment] re FDA-2008-P-0411-0017",Supporting & Related Material,RC-Reply Comment (Supporting and Related Material),2009-06-17T04:00:00Z,2009,6,,,2009-06-18T00:16:16Z,,0,0,09000064809d05fc
FDA-2008-P-0411-0019,FDA,FDA-2008-P-0411,"Exhibit 2 - ""Winston & Strawn LLP (on behalf of Caraco) to FDA/CDER, re: request for Correction, June 1, 2009"" - [Caraco Pharmaceuticals Laboratories, LTD - (Winston & Strawn LLP) - Reply Comment] re FDA-2008-P-0411-0017",Supporting & Related Material,RC-Reply Comment (Supporting and Related Material),2009-06-17T04:00:00Z,2009,6,,,2009-06-18T00:15:29Z,,0,0,09000064809d05fb